Hexarelin Dosing & Protocols — Research Reference

Hexarelin is the most potent member of the GHRP class on a per-microgram basis and is uniquely cited in cardioprotective research because of its secondary CD36 binding. Its high potency and pronounced receptor-desensitization profile distinguish it from ipamorelin and the GHRP-2/6 pair.

Reconstitution for Research

Hexarelin is typically supplied lyophilized in 2 mg or 5 mg vials. A 2 mL bacteriostatic-water reconstitution yields 1 mg/mL (2 mg vial) or 2.5 mg/mL (5 mg vial). At 1 mg/mL, 10 IU on a U-100 syringe delivers 100 mcg. Refrigerate at 2–8 °C and use within the COA's documented window.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Entry / pulse characterization | 50–100 mcg per dose | Threshold for observable GH pulse; lower than other GHRPs because of higher potency | | Standard GH-pulse studies | 100 mcg, 1–2× daily | Most cited tier; capped low because of desensitization | | Cardioprotective research | 50–100 mcg/kg in rodent models | CD36 arm engaged independent of pituitary GH response |

Scheduling

Subcutaneous injection is the most-cited route. Most published protocols hold to once- or twice-daily dosing with strict short-cycle structure (4–6 weeks on, 4-week washout) because hexarelin produces the most pronounced receptor desensitization of the GHRP class. Continuous chronic dosing progressively flattens the GH response in primate work — this is the central scheduling constraint.

Cortisol and Prolactin Considerations

Hexarelin elevates cortisol and prolactin more than ipamorelin and similar to or above GHRP-2. Researchers building pure GH-pulse protocols often choose ipamorelin instead; researchers studying cardioprotection or accepting the cortisol signal use hexarelin.

Quality and Identity Verification

LC-MS confirmation of molecular weight (887.04 Da) and HPLC purity ≥98% are the standard acceptance criteria. Endotoxin testing applies for parenteral animal models.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Deghenghi R, Cananzi MM, Torsello A, et al. GH-releasing activity of Hexarelin in infant and adult rats. Life Sci. 1994;54(18):1321–1328.
2. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides. Circ Res. 2002;90(8):844–849.
3. Imbimbo BP, Mant T, Edwards M, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421–425.